ADVA
19.5.2020 09:02:13 CEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that dacoso is using its cloud-native security solution, ConnectGuard™ Cloud, to offer secure managed services. The virtualized encryption technology will give dacoso’s customers comprehensive data protection in cloud environments. With unprecedented scale and efficiency, dacoso will be able to roll out secure connectivity within minutes, safeguarding private, public, and edge/branch clouds at Layers 2, 3 and 4. Managed centrally in dacoso’s network by ADVA’s Ensemble Controller , the VPN services offer a major boost to the region’s businesses as they look to reduce costs and enhance flexibility by migrating more of their data and applications to the cloud. Now dacoso’s enterprise customers can harness the latest cloud tools while ensuring data integrity, regulatory compliance and true peace of mind for their end users.
“We’re excited to be offering our customers the comprehensive protection of ADVA’s ConnectGuard™ Cloud technology. For many of them, total cloud security is key to their business needs. By providing strong and flexible data protection in virtual environments, we’re enabling our customers to realize their full potential by accessing cloud applications with complete peace of mind,” said Karsten Geise, head of business and product development, dacoso. “We’re convinced by the robust security and performance benefits of ConnectGuard Cloud™. So much so that we’re already harnessing the solutions to protect our own branch and cloud locations. We understand its power to protect mission-critical data while also reducing costs and enhancing network utilization.”
Implemented entirely in software, ADVA’s ConnectGuard™ Cloud is a highly scalable, standards-compliant encryption solution that provides hybrid and multi-cloud environments with the ultimate defense against cyber threats. It enables dacoso to offer its customers high-performance, transport-layer-independent security with none of the performance issues of IPSec-based technologies. As a far more efficient and cost-effective alternative to hardware security appliances, ConnectGuard™ Cloud empowers dacoso’s customers to extend encryption to remote workers and branch offices by leveraging low-cost uCPE platforms. What’s more, with zero-touch provisioning, dacoso can roll out fully secured cloud connectivity almost instantly without any manual configuration.
“Our partnership with dacoso is great news for a huge number of enterprises across this region who are currently undergoing their digital transformation. With more and more of dacoso’s customers moving their workloads to cloud environments, our ConnectGuard™ Cloud technology provides the ideal way to ensure privacy and data integrity while keeping cost and complexity low,” commented Hartmut Müller-Leitloff, SVP, sales, EMEA, ADVA. “As a virtualized encryption solution with zero-touch provisioning and automated key management, our ConnectGuard™ Cloud is the most readily scalable option available. It improves operational simplicity and latency performance compared to appliance-based encryption methods. What’s more, it keeps latency at its lowest levels – a key requirement for many emerging cloud applications.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com
.
About dacoso
dacoso offers solutions for Connectivity, Virtual Networking and Cyber Security. The IT service provider thereby addresses companies that need their data to be highly available and secure yet without sacrificing agility. dacoso’s services comprise, among other, optical data links encrypted to satisfy BSI requirements (Federal Office for Information Security), a certified Security Operations Center, Managed Security Services and virtualization solutions to increase the dynamic performance of networks. dacoso GmbH is an owner-managed company headquartered in Langen near Frankfurt a.M. with a further 11 locations in Germany, Austria and Switzerland. www.dacoso.com
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200519005058/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 13:30:00 CEST | Press release
-With this expansion, any variant that results in production of CFTR protein is now included in the indication for ALYFTREK and TRIKAFTA, reinforcing the impact these medicines have, regardless of the location of the variant in the CFTR protein--Approximately 800 more people with CF in the US are now eligible for a CFTR modulator for the first time- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported b
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer1.4.2026 13:30:00 CEST | Press release
A Landmark Registrational Study Aiming to Redefine Outcomes in MSS mCRC Which Represents Approximately 95% of Metastatic Colorectal Cancer CasesColorectal Cancer Has Become the Leading Cause of Cancer-related Death in Adults Under Age 50 Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy. This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooper
Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 13:19:00 CEST | Press release
Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user
Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 13:00:00 CEST | Press release
Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin
Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond1.4.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460). Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive capabilities in drug development, manufacturing, and commercialization. The collaboration will focus on advancing innovative therapies across multiple disease areas, including weight loss, leveraging complementary strengths to drive synergies and establish a long-term strategic partnership. Sihuan Pharmaceutical highly values the strength of Biocytogen’s technology platforms. In this collaboration, Biocytogen will leverage its integrated platforms, including proprietary target-humanized mouse models and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom